Cost‐Effectiveness of the Early Arthritis Clinic Organizational Model
Authors' conclusion
Despite an expected increase in outpatient costs (visits and diagnostic tests) and pharmaceutical costs, the reduction in terms of number and length of hospitalizations and the higher adherence to international quality-of-care guidelines support the effectiveness of the EAC model.
Study context
- Population
- Patients with a new diagnosis of rheumatoid arthritis (RA) (mean age 55.4 years; 70% female)4 non-EAC controls matched per early arthritis clinic (EAC) patient
- Exposure
- Early arthritis clinic vs current standard of care
- EACn = 430
- Outcome
- Mean health care costs (outpatient, inpatient, pharmaceutical, global) and effectiveness (number and length of hospitalization, quality of care); ICER
- Follow-up
- 2 years
Methodological detailsadministrative health databases, matched (4 non-EAC controls per EAC patient), cost-effectiveness analysis
- Administrative health databases
- Matched (4 non-EAC controls per EAC patient)
- Cost-effectiveness analysis
Main finding
As reported in the abstract
Mean costs
| Group | Value | Outpatient costs |
|---|---|---|
| EAC | mean 2,602 euros | 2,447 euros |
| non-EAC | mean 1,945 euros | 1,778 euros |
Value
EACmean 2,602 euros
non-EACmean 1,945 euros
Outpatient costs
EAC2,447 euros
non-EAC1,778 euros
Observational data: associations, not effects.
Original publication
Cost‐Effectiveness of the Early Arthritis Clinic Organizational Model. Arthritis Care Res (Hoboken). Published 5 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →